-
-
-
-
-
-
-
Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward
-
-
-
-
-
-
-
CORRECTING AND REPLACING: Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Annual mRNA-based Therapeutics Summit
-
-
-
-
-
-
-
Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics
-
-
-
-
-
-
-
Applied DNA Sciences (APDN) Receives Notice of Allowance for U.S. Patent Covering Fundamental Aspect of its Linea IVT Platform
-
-
-
-
-
-
-
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
-
-
-
-
-
-
Applied DNA Sciences (APDN) Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea RNAP
-
-
-
-
-
-
-
Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
1,157,716 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

